Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 12/20 | 0.75 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2324139 | 0.91 | FPR2 (0.64) | FPR2HCRTR2KDM4EMEN1KMT2A | |
| SCHEMBL2329254 | 0.90 | FPR2 (0.66) | FPR2HCRTR2HCRTR1MEN1KMT2A | |
| SCHEMBL2328793 | 0.90 | FPR2 (0.62) | FPR2HCRTR2KDM4E | |
| SCHEMBL2327498 | 0.89 | FPR2 (0.60) | FPR2HCRTR2HCRTR1 | |
| SCHEMBL2324747 | 0.89 | FPR2 (0.67) | FPR2HCRTR2HCRTR1MEN1KMT2A | |
| SCHEMBL2326935 | 0.87 | FPR2 (0.58) | FPR2HCRTR2HCRTR1 | |
| SCHEMBL2330390 | 0.86 | FPR2 (0.62) | FPR2 | |
| SCHEMBL1166171 | 0.86 | FPR2 (0.75) | FPR2HCRTR2KDM4EHCRTR1MEN1 | |
| SCHEMBL2327710 | 0.86 | FPR2 (1.00) | FPR2HCRTR2 | |
| SCHEMBL15284387 | 0.85 | FPR2 (0.62) | FPR2HCRTR2KDM4EHCRTR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225231-B1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-17 | — | — | EP | claimed |
| EP-2649068-B1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-8846733-B2 | Oxazolyl-methylether derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-09-30 | — | — | US | disclosed |
| US-8846733-B2 | Oxazolyl-methylether derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20130261159-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261159-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-03 | — | — | US | disclosed |
| WO-2012077049-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-14 | — | — | WO | disclosed |
| EP-2225231-B1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261159-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | P2RX7, ADORA3, P2RX1 | FPR2 275/4885HCRTR2 77/4885KDM4E 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.